BIKTARVY Drug Patent Profile

Which patents cover Biktarvy, and what generic alternatives are available?

Biktarvy is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are nine patents protecting this drug and two Paragraph IV challenges.

This drug has three hundred and four patent family members in fifty countries.

The generic ingredient in BIKTARVY is bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate. Two suppliers are listed for this compound. Additional details are available on the bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Biktarvy

Biktarvy was eligible for patent challenges on February 7, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 8, 2036. This may change due to patent challenges or generic licensing.

There have been twenty patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for BIKTARVY

International Patents:	304
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Clinical Trials:	44
Drug Prices:	Drug price information for BIKTARVY
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BIKTARVY
What excipients (inactive ingredients) are in BIKTARVY?	BIKTARVY excipients list
DailyMed Link:	BIKTARVY at DailyMed

See drug prices for BIKTARVY

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BIKTARVY

Constraining patent/regulatory exclusivity:

10,548,846

NDA:

210251

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BIKTARVY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Gilead Sciences	NA
Brigham and Women's Hospital	NA
Trutag Technologies	NA

See all BIKTARVY clinical trials

Pharmacology for BIKTARVY

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Nucleoside Reverse Transcriptase Inhibitors

Paragraph IV (Patent) Challenges for BIKTARVY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BIKTARVY	Tablets	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	30 mg/120 mg/ 15 mg	210251	1	2023-09-28
BIKTARVY	Tablets	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	50 mg/200 mg/ 25 mg	210251	3	2022-02-07

US Patents and Regulatory Information for BIKTARVY

BIKTARVY is protected by nine US patents and six FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 10,548,846.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-002	Oct 7, 2021		RX	Yes	No	10,385,067
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-001	Feb 7, 2018		RX	Yes	Yes	9,708,342		Y	Y
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-001	Feb 7, 2018		RX	Yes	Yes

Expired US Patents for BIKTARVY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-001	Feb 7, 2018	7,803,788
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-001	Feb 7, 2018	6,642,245
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-002	Oct 7, 2021	7,803,788

International Patents for BIKTARVY

When does loss-of-exclusivity occur for BIKTARVY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Cuba

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

Hong Kong

Israel

Japan

Mexico

New Zealand

Peru

Philippines

Poland

Portugal

Singapore

Slovenia

South Korea

Spain

Taiwan

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BIKTARVY around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	100903
Australia	2015276860
Australia	2018203175

Supplementary Protection Certificates for BIKTARVY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1301519	2016/014	Ireland		PRODUCT NAME: TENOFOVIR ALAFENAMIDE OR A SALT OR SOLVATE THEREOF, IN PARTICULAR TENOFOVIR ALAFENAMIDE FUMARATE; REGISTRATION NO/DATE: EU/1/15/1061/001-EU/1/15/1061/002 20151119
0513200	91073	Luxembourg		91073, EXPIRES: 20160131
0513200	300148	Netherlands		300148, 20110131, EXPIRES: 20160130

BIKTARVY Market Dynamics and Financial Trajectory (Biktarvy, bictegravir/emtricitabine/tenofovir alafenamide)

Last updated: July 22, 2026

Executive summary. BIKTARVY (bictegravir/emtricitabine/tenofovir alafenamide; Biktarvy) is a high-performing, category-leading single-tablet regimen in HIV treatment, anchored by clinical durability, resistance barrier, and strong tolerability. Financially, the product has sustained blockbuster scale driven by new starts, switch demand from prior antiretrovirals, and retention in long-term care. Competitive pressure is primarily from other integrase-based regimens and long-acting investigational/late-stage programs, but near-term risk is moderated by Biktarvy’s regimen simplicity, evidence base, and payer familiarity. Near-term market dynamics center on formulary positioning, generic/biosimilar adjacency risk in the broader HIV market (not Biktarvy itself, due to active IP), and the pace of uptake of alternative fixed-dose combinations and long-acting injectables.

---

What drives BIKTARVY market dynamics in US and international HIV therapy?

Short answer: Biktarvy’s market behavior is driven by (1) integrase-class efficacy and durability, (2) simplicity and adherence from one-tablet dosing, (3) clinician comfort and payer access, and (4) switching patterns from older regimens.

Which factors most affect demand for BIKTARVY?

Key demand levers observed in HIV commercial dynamics:

• New patient starts: Integrase-based first-line regimens dominate guideline preference; Biktarvy captures share where payers and prescribers favor high-efficacy, low-management options.
• Switching and retention: Patients stable on other regimens often switch for regimen simplification or tolerability, reinforcing steady revenue.
• Formulary access: Access decisions (preferred status, prior authorization friction, and step edits) are a main determinant of uptake and refill continuity.
• Resistance and treatment-experienced subsegments: Biktarvy’s performance in broader practice settings supports persistence of prescriptions across lines of therapy, reducing churn versus weaker alternatives.
• Safety/tolerability: Renal and bone safety improvements are critical in real-world prescribing because they reduce monitoring burden and discontinuations.

How do competitors influence BIKTARVY pricing and share?

Primary competitive pressure comes from:

• Other fixed-dose integrase-based single-tablet regimens in first-line and switch populations.
• Long-acting injectables in pipeline and late-stage development that could shift preference in select patient segments if outcomes and access align.

Competitors’ ability to affect Biktarvy is typically constrained by:

• Their requirement for dosing complexity or specific patient selection.
• Payer adoption lags for newer regimens until they establish cost-effectiveness and real-world durability.

---

How has BIKTARVY performed financially since launch through the most recent reporting periods?

Short answer: Biktarvy has remained in blockbuster territory for sustained periods, supported by consistent demand growth and retention. Financial trajectory is best read through Gilead’s reported revenue mix for HIV products and the product’s ongoing share in integrase-based regimens.

Where does BIKTARVY revenue show up in financial reporting?

BIKTARVY is reported within Gilead’s HIV franchise revenue disclosures; it is not typically broken out as a standalone line item in every jurisdictional filing, but its performance is reflected in:

• Gilead’s total revenue and HIV segment trends
• HIV product sales composition and commentary around US share and international momentum in investor presentations

What commercial factors shape BIKTARVY’s year-to-year financial path?

• US formulary position: Preferred coverage reduces friction and supports stable prescription volumes.
• International scaling and procurement behavior: Tender cycles and payer budgets influence quarterly step-changes.
• Switching vs. churn: Biktarvy’s revenue resilience is linked to high retention and low discontinuation in stable patients.
• Pricing environment: Net price is shaped by rebates, discounts, and government program procurement dynamics.

---

When does BIKTARVY lose exclusivity, and how does that affect financial risk?

Short answer: The exclusivity and patent wall for Biktarvy is multi-layered and jurisdiction-specific. Financial risk rises as patent and exclusivity cliffs approach, particularly if generics can launch without waiting for all relevant Orange Book and patent-scope barriers.

What exclusivity protection layers are relevant to revenue protection?

For a small-molecule HIV fixed-dose regimen like Biktarvy, the revenue protection stack typically includes:

• Regulatory exclusivities tied to FDA marketing authorization (application-level exclusivity)
• Patent estate protecting drug substance, drug product, and potentially method-of-use and formulation variants
• Orange Book-listed patents that constrain Paragraph IV pathways for generic entry

How do patent cliffs translate into market outcomes?

When exclusivity erodes, typical post-cliff dynamics include:

• Rapid share loss for the branded product due to generic substitution in commercially insured and government formularies.
• Legal and settlement outcomes that can delay launch even when a Paragraph IV is filed.
• Payer preference shifts to lower-cost alternatives unless branded manufacturer succeeds in defending patents or obtaining meaningful settlement terms.

---

What is the Orange Book status of BIKTARVY and what patents matter most?

Short answer: Orange Book listings identify the key patent barriers that control generic and biosimilar-adjacent entry risk for Biktarvy’s FDA-licensed versions.

How do Orange Book patents create entry barriers for generics?

• Generic filers must address each Orange Book patent listed for the NDA and for the specific strengths and dosage forms.
• Patent challenges (e.g., Paragraph IV) trigger automatic litigation stay dynamics that can delay launch.

Which patent types usually dominate market-impact risk?

For branded HIV fixed-dose combinations, patents most often controlling entry are:

• Composition-of-matter for the active ingredient(s)
• Fixed-dose combination claims
• Crystalline form / polymorph and formulation claims
• Manufacturing process patents
• Method-of-use claims that can remain relevant even if core composition barriers are cleared

---

Which companies are challenging BIKTARVY patents via Paragraph IV, and what litigation outcomes matter?

Short answer: Generic entry risk is concentrated in Paragraph IV filings targeting Orange Book-listed patents for the NDA(s). Litigation outcomes and settlement terms determine launch timing and market impact.

What to monitor in BIKTARVY patent litigation

Key litigation variables affecting financial impact:

• Whether the case includes the most restrictive, combination-defining claims
• District court claim construction outcomes and Federal Circuit affirmance
• Settlement terms such as “no-early-entry” provisions
• Design-around success, if claim scope allows alternatives

How settlement structures typically change market outcomes

Settlement can produce:

• Delayed generic launch even after challenge filings
• Partial launch agreements (launching only certain strengths) depending on claim scope
• Branding company incentives for earlier settlement to reduce uncertainty

---

What formulation and dosing patents protect BIKTARVY, and do they block generic substitution?

Short answer: If formulation-specific patents are Orange Book listed, they can block generic substitution for the protected dosage forms or require design-around.

What formulation elements typically get protected for HIV fixed-dose tablets?

• Tablet composition and excipient systems that improve dissolution and stability
• Specific manufacturing steps that achieve consistent release
• Solid-state forms of one or more components that affect bioavailability

How strong are formulation patents in practice?

Formulation patents tend to be most commercially decisive when:

• They are broadly worded and tied to Orange Book listing for the marketed product
• They are central to demonstrating equivalence on the generic label

---

How does BIKTARVY compare with other top integrase-based regimens on market share and payer adoption?

Short answer: Biktarvy competes with other integrase-based fixed-dose combinations, and its advantage typically shows up in lower management burden and high prescriber confidence.

What matters in head-to-head regimen comparisons that influence payer decisions?

• Switch rate from competitor regimens
• Persistence on therapy (discontinuation and refill behavior)
• Real-world tolerability in comorbid populations
• Clinical evidence depth for treatment-naive and treatment-experienced settings

What commercial signals indicate share wins vs. losses?

• Changes in formularies and preferred tier status
• Growth or contraction in prescriptions in large pharmacy benefit managers
• International procurement bids and tender outcomes

---

What biosimilar or biologics-like risks exist for BIKTARVY?

Short answer: Biktarvy is a small-molecule combination product; biosimilar pathways are not the relevant framework. The material competitive risk comes from generics and authorized generics, not biosimilar substitution.

What replaces “biosimilar risk” in small-molecule HIV franchises?

• Generic small-molecule entry via ANDA pathways
• Patent litigation and stays affecting launch
• Authorized generic agreements that can undermine brand margins even without full generic substitution

---

How might generic launch scenarios for BIKTARVY unfold?

Short answer: Generic entry for Biktarvy would typically proceed through ANDA approvals contingent on patent carve-outs and litigation outcomes. The market impact depends on whether the launch occurs at full label coverage or partial strengths, and on payer substitution speed.

Generic entry scenarios that affect near-term revenue

1. Full launch after all barriers cleared
   • Fast brand erosion in commercially insured and government formularies
2. Staggered or strength-limited launch
   • Partial volume loss and possible continued brand strength in remaining strengths
3. Delayed launch via settlement
   • Continued branded revenue longer than implied by the mere existence of a Paragraph IV filing
4. Design-around outcomes
   • If generic avoids key claims, launch timing could advance despite ongoing disputes

---

What regulatory milestones and FDA pathway choices influence BIKTARVY’s market access?

Short answer: FDA authorization enables label expansions that can widen eligibility and increase patient pool. Subsequent label updates can also affect switching behavior and coverage criteria.

How label expansions change commercial trajectory

• Expanded indications or patient eligibility can broaden uptake beyond narrow subpopulations.
• New safety or drug-drug interaction guidance can shift clinician confidence.

---

What is the revenue exposure of BIKTARVY to the US pricing and rebate environment?

Short answer: Like most branded HIV drugs, Biktarvy’s reported net revenue is sensitive to rebate programs, government pricing rules, and payer contracting.

How net price mechanics typically impact blockbuster HIV products

• Manufacturer rebates reduce net price but support formulary placement.
• Government programs and 340B-like channels can stabilize volume while pressuring net revenue per unit.
• Patent or exclusivity transitions increase competitive discounting and rebate intensity.

---

Key Takeaways

• Biktarvy’s revenue trajectory is driven by durable integrase-based efficacy, one-tablet simplicity, and strong real-world tolerability that supports persistence and switching.
• Market dynamics are mainly competition among fixed-dose integrase regimens and selective uptake of longer-acting strategies, rather than biosimilar risk.
• Financial risk is determined by the depth and timing of the Orange Book patent estate and exclusivity layers, plus Paragraph IV litigation outcomes and any settlements.
• Post-exclusivity outcomes typically produce rapid market share loss, with magnitude shaped by strength coverage, payer substitution speed, and the availability of authorized or generic alternatives.

---

FAQs

1) What strengthens BIKTARVY’s payer access over competing integrase regimens?
Preferred formulary status, low prior authorization friction, and evidence-backed durability that supports persistence.

2) How do label expansions for Biktarvy typically affect prescription volume?
They widen eligible patient pools and increase prescriber confidence in switching, supporting incremental demand.

3) What is the biggest near-term threat to BIKTARVY revenue growth?
Alternative fixed-dose integrase regimens gaining formulary preference and incremental patient share shifts toward long-acting injectable strategies.

4) How do patent litigation and stays change generic launch timing for BIKTARVY?
They can delay approval or launch via statutory stays and settlement-driven “no-early-entry” terms.

5) If generics enter BIKTARVY, what determines how fast branded revenue erodes?
Orange Book-patent scope at launch (strength coverage), payer substitution speed, and net price compression through rebates and contracting.

---

References (APA)

1. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
2. Gilead Sciences, Inc. Investor Relations. (n.d.). SEC filings and quarterly earnings releases. https://www.gilead.com/investors
3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

DrugChatter Q&A for BIKTARVY

Biktarvy worldwide sales 2023 billion?
Biktarvy generic or biosimilar version?
How much does biktarvy cost in ghana 2021?
Who is the manufacturer of biktarvy?
When will biktarvy patent expire?